Diagnosis of ACTH resistance syndrome is a dubious disease in the field of blood tumors, with clinical manifestations being complex and often involving multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological activation.
Platforms can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of ACTH resistance syndrome requires individualized development, typically including multidimensional management, including drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of ACTH resistance syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.